Amedi.sk
Dovoľujeme si Vás upozorniť, že naša web stránka
je určená iba pre odbornú lekársku verejnosť.
Časopis Clinical urology – Článok What are the features of selected descriptive indicators of kidney cancer occurrence in the slovak republic and abroad?

Clinical urology

Postgraduate scientific medical journal. Magazine Slovak Association of Urology.
Period 3x per year
1336-7579
The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Clinical urology
Clinical urology
Postgraduate scientific medical journal. Magazine Slovak Association of Urology.
Period 3x per year
Predplatné
Téma: Overview works

What are the features of selected descriptive indicators of kidney cancer occurrence in the slovak republic and abroad?

Martina Ondrušová1,2, Dalibor Ondruš3

Backgrounds: The Slovak Republic (SR) is for many years among the countries with the highest global incidence of kidney cancer. Character of mortality from kidney cancers has been changed in the last years. This study analysed the incidence and resulting mortality and the possible reasons for any differences discovered in the SR in correlation with other countries. Material and Methods: Analyses of national data take into account the period 1968-2006. The trends have been extracted using linear regression model and are presented with corresponding 95 % Confidence Intervals (CI) and p-value with null hypothesis being constant with time. Predictions of incidence and prevalence for the year 2010 have been calculated and the clinical stages of the disease were presented. Results: In 1980-1994, the average increase of standardized incidence of kidney cancer in males in the SR represented 0.48/100 000 (95 % CI = 0.41 - 0.55; p < 0.0001), however, in 1994-2006 the trends slowed down to 0.21/100 000 (95 % CI = 0.037 - 0.382; p = 0.02). In females, the trends in 1980-1994 were 0.24/100 000 (95 % CI = 0.19 - 0.28; p < 0.0001) and 0.13/100 000 in 1994-2006 (95 % CI = 0.04 - 0.22; p = 0.007). Mortality culminates as well as incidence in about the year 1994, later the stabilization of mortality was reported in both sexes. In the SR just slight changes in the percentage of kidney cancer clinical stages in 2000-2006 have been recorded. Conclusion: The increase of total kidney cancer incidence is not explained only by the growth of asymptomatic localized tumours, but it likely reflects actual growth of new cases of the disease. The assumed cause of the mortality stabilization and slowdown of the incidence growth after its previous culmination in 1994 is the decline of smoking and obesity prevalence in the last decades in men, although this fact does not reflect situation in women.

kidney cancer –incidence, mortality, clinical stages, risk factors
Klin. urol. 2012; 8 (1): 8-13

Ročník 2012  Témy časopisu Clinical urology 1 / 2012

Overview works

Martina Ondrušová1,2, Dalibor Ondruš3
Dalibor Pacík
Roman Tomaškin, Boris Eliáš, Ján Kliment
Silvia Mahmood1, Monika Kmeťová-Sivoňová1, Dušan Dobrota1, Marta Pisková1, Róbert Dušenka1,2, Svetlana Grobarčíková2 a Ján Kliment2

Vladimír Bartoš1, Oľga Zacharová1, Dušan Pokorný1, Roman Mráz2, Juraj Mikuláš2, Peter Laurinc2

Ján Švihra1, Ivana Zigová2, Milan Švec3, Eva Šulcová4

Monika Kmeťová Sivoňova1, Marta Pisková1, Dušan Dobrota1, Róbert Dušenka1,2, Svetlana Grobarčíková2, Silvia Mahmood1, Ján Kliment2
1
3 1
3 1
3 1
3 2 1
3 1
3 1
2 1
2 1
3 2 1
3 2 1
2 1
3 2 1
3 2 1
1
Nie sú dostupné žiadne voľne dostupné články
CHAIRMAN OF THE EDITORIAL BOARD
prof. MUDr. Ján Kliment, CSc.

MEMBERS OF THE EDITORIAL BOARD
prof. Andrzej Borówka, M.D., PhD.
prof. MUDr. Ján Breza, DrSc.
prof. MUDr. Peter Bujdák, PhD.
prof. MUDr. Tomáš Hanuš, DrSc.
doc. MUDr. Ladislav Jarolím, CSc.
doc. MUDr. Ján Ľupták, PhD.
doc. MUDr. Jozef Marenčák, PhD.
doc. MUDr. Ivan Minčík, PhD.
prof. MUDr. Dalibor Ondruš, DrSc.
prof. Imre Romics, M.D., PhD.
doc. MUDr. Vladimír Študent, PhD.
prof. MUDr. Ján Švihra, PhD.
prof. MUDr. Ladislav Valanský, PhD.
doc. MUDr. František Záťura, PhD.
MUDr. Peter Zvara, PhD.

PROFESSIONAL EDITOR
prof. MUDr. Ján Švihra, PhD.

EDITOR-IN-CHIEF
Ing. Danica Paulenová
e-mail: paulenova@amedi.sk

GRAPHIC LAYOUT AND TYPESETTING
Lucia Vecseiová
e-mail: dtp@amedi.sk

MARKETING MANAGER
Ing. Dana Chodasová
mobil: 0903 224 625
e-mail: marketing@amedi.sk

ECONOMY AND SUBSCRIPTIONS
Ing. Mária Štecková
telefón: 02/55 64 72 48
mobil: 0911 117 949
e-mail: ekonom@amedi.sk

LANGUAGE PROOFREADING
Mgr. Eva Doktorová

PROOFREADING OF ENGLISH TEXTS
Mgr. Jana Bábelová
SECTIONS

OVERVIEW PAPERS
The latest knowledge on disease and disease groups aetiology, pathogenesis, diagnoses and therapy. Maximum extent is 7 pages of text (font ARIAL or TIMES, font size 12, line spacing 1.5). In case of more extensive theme elaboration it is possible to divide the paper to several parts after agreement with editorial office.

ORIGINAL PAPERS
Structuring: introduction, clinical group and methods, results, discussion, conclusion, bibliography

DIAGNOSTIC AND THERAPEUTICAL ALGORITHMS
Diagnosis and therapy processed into tables and schemes, with minimum text, with emphasis on conciseness and clarity.

CASE STUDY
Maximum extent is 3 pages. Structuring: summary, case study, conclusion, bibliography.

MISCELLANEOUS
Reaction to overview articles, news in the field of diagnostics, therapy, trial results (maximum 3 pages), reports from professional events, abstracts from scientific work published abroad, not older than 1 year. Maximum extend is 1 page. Title of the paper in Slovak/Czech, authors, workplace, then title of the paper in English with full citation.


MANUSCRIPT ELABORATION

Write the paper on computer in any common text editor.
write full length of lines (do not use ENTER at the end of a line)
- do not arrange text into columns
- do not do page make-up, put tables at the end of the paper
- distinguish precisely numbers 1, 0 and letters l, O
- use always parentheses ( )
- explain abbreviations always when first used


MANUSCRIPT REQUIREMENTS

1. An accurate paper title, names and surnames of all authors including titles, authors` workplace. The first author address including the phone number, fax and e-mail address.
2. Summary - structured abstract: goal of work, material and methods (do not state the name of the workplace), results, conclusion
3. Key words - in the extent of 3-6.
Write in 1st or 3rd person singular or plural (unify according the type of an article).
4. English translation: the title of the paper, summary, key words 5. Text
If you insert pictures into a document, send also their original files in "jpg" format, create graphs in Excel and send also their original files. If you send photo documentation via post office, please, send just high-class originals. Mark each original by a number, under which it is mentioned in the text. Write in 1st or 3rd person singular or plural (unify according the type of an article). In the text do not use highlighting of the text as e.g. underlined text, bold, with exception of titles, references to pictures, tables, graphs.

6. Bibliography
Citations are numbered chronologically in bold, references in the text are stated by the number of citations in parentheses.
Citation means in general: the surname of the author (authors), title of the work, year of issuing, volume, pages.
Do not use "ét al.", but state all authors.

Examples of citations:
1. Shaheen NJ, Crosby NA, Bozymski EM, et al. Is there publication bias in the reporting cancer risk in Barrett´ esophagus? Gastroenterology 2000; 119: 333-338.
2. Stenestrand U, Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA): Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
3. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
4. Jurkovičová O, Spitzerová H, Cagáň S. Komorové arytmie a náhla srdcová smrť pri akútnom infarkte myokardu. Bratisl Lek Listy 1997; 98: 379-389.
5. Osborne BE. The electrocardiogram of the rat. In: Budden R, Detweiler DK, Zbinden G. The rat electrocardiogram in pharmacology and toxicology. Oxford: Pergamon Press 1981:15-27.

Do not use dots after first names in citations. Do not use colon but dot after names of authors. Use semi-colon after the year of publishing, colon is before pages.

The editorial board reserves the right to make small stylistic changes in the paper. If it is necessary to shorten the paper, the consent of the author will be required. All articles are reviewed.

Which of following factors is not related to rosacea?
a. genetic predisposition
b. Scandinavian origin
c. propionibacterium acnes
d. endothelial growth factor

The editorial board reserves the right to make small stylistic changes in the paper. If it is necessary to shorten the paper, the consent of the author will be required. All articles are reviewed.

All published papers are paid.

Send contributions in the e-mail to the address: paulenova@amedi.sk
Period 3x per year
1336-7579
The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Clinical urology
Clinical urology
Postgraduate scientific medical journal. Magazine Slovak Association of Urology.
Period 3x per year
Predplatné